SG11201708759YA - Improved uricase sequences and methods of treatment - Google Patents

Improved uricase sequences and methods of treatment

Info

Publication number
SG11201708759YA
SG11201708759YA SG11201708759YA SG11201708759YA SG11201708759YA SG 11201708759Y A SG11201708759Y A SG 11201708759YA SG 11201708759Y A SG11201708759Y A SG 11201708759YA SG 11201708759Y A SG11201708759Y A SG 11201708759YA SG 11201708759Y A SG11201708759Y A SG 11201708759YA
Authority
SG
Singapore
Prior art keywords
treatment
methods
uricase sequences
improved
improved uricase
Prior art date
Application number
SG11201708759YA
Other languages
English (en)
Inventor
Manuel Baca
Andrew C Nyborg
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of SG11201708759YA publication Critical patent/SG11201708759YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12N9/0048—Uricase (1.7.3.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201708759YA 2015-05-15 2016-05-13 Improved uricase sequences and methods of treatment SG11201708759YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562162280P 2015-05-15 2015-05-15
PCT/US2016/032415 WO2016187026A1 (en) 2015-05-15 2016-05-13 Improved uricase sequences and methods of treatment

Publications (1)

Publication Number Publication Date
SG11201708759YA true SG11201708759YA (en) 2017-11-29

Family

ID=57320301

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201910522TA SG10201910522TA (en) 2015-05-15 2016-05-13 Improved uricase sequences and methods of treatment
SG11201708759YA SG11201708759YA (en) 2015-05-15 2016-05-13 Improved uricase sequences and methods of treatment

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201910522TA SG10201910522TA (en) 2015-05-15 2016-05-13 Improved uricase sequences and methods of treatment

Country Status (18)

Country Link
US (3) US11098289B2 (enExample)
EP (1) EP3294322A4 (enExample)
JP (2) JP2018515101A (enExample)
KR (1) KR20180002828A (enExample)
CN (1) CN107614007B (enExample)
AU (2) AU2016265677B2 (enExample)
BR (1) BR112017024212A2 (enExample)
CA (1) CA2984926A1 (enExample)
CL (1) CL2017002774A1 (enExample)
CO (1) CO2017012454A2 (enExample)
HK (1) HK1252542A1 (enExample)
IL (1) IL255403A0 (enExample)
MX (1) MX2017014547A (enExample)
MY (1) MY190411A (enExample)
RU (1) RU2752497C2 (enExample)
SG (2) SG10201910522TA (enExample)
WO (1) WO2016187026A1 (enExample)
ZA (1) ZA201708507B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107614007B (zh) 2015-05-15 2022-03-25 免疫医疗有限责任公司 改进的尿酸酶序列和治疗方法
CN106554948B (zh) * 2015-09-29 2019-06-25 上海生物制品研究所有限责任公司 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用
CN112410313A (zh) * 2019-08-20 2021-02-26 中国科学院上海药物研究所 一种高热稳定性尿酸酶及其应用
CN112646790A (zh) * 2019-10-11 2021-04-13 上海君实生物医药科技股份有限公司 改进的尿酸酶及其用于治疗高尿酸血症的方法
WO2021083278A1 (en) * 2019-10-29 2021-05-06 Westlake Therapeutics (Hangzhou) Co. Limited Engineering red blood cells for treating gout and hyperuricemia diseases
JP2023543045A (ja) 2020-09-25 2023-10-12 プロアブテック インコーポレイテッド 尿酸酸化酵素－アルブミン結合体、その製造方法および用途
WO2022081774A1 (en) * 2020-10-13 2022-04-21 University Of Florida Research Foundation, Incorporated Self-assembling uricase fusion peptides
KR20230110281A (ko) 2020-11-03 2023-07-21 프로탈릭스 리미티드 변형된 유리카제(uricase) 및 이의 용도
CN114438048B (zh) * 2020-11-05 2024-10-22 重庆派金生物科技有限公司 尿酸氧化酶制剂及其应用
CN115197923B (zh) * 2021-04-09 2024-11-26 上海君实生物医药科技股份有限公司 尿酸酶、其药物组合物及其用途
WO2023282556A1 (ko) * 2021-07-08 2023-01-12 주식회사 프로앱텍 Arthrobacter globiformis 유래 요산산화효소-알부민 접합체, 그 제조방법 및 그 용도
KR20240083169A (ko) * 2021-09-23 2024-06-11 주식회사 프로앱텍 Apn 그룹을 포함하는 링커 및 이를 이용하여 제조된 기능성 폴리펩티드 변이체-알부민 컨쥬게이트
WO2023064732A1 (en) * 2021-10-15 2023-04-20 Georgia State University Research Foundation, Inc. Delivery of therapeutic recombinant uricase using nanoparticles
CN119752761B (zh) * 2025-03-07 2025-06-17 北京化工大学 一种高产heparosan的基因工程菌及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09154581A (ja) * 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
JP2002524053A (ja) 1998-08-06 2002-08-06 デューク・ユニバーシティー 尿酸オキシダーゼ
RU2278680C2 (ru) * 1998-08-06 2006-06-27 Маунтэн Вью Фармасьютикэлз, Инк. Способ изолирования тетрамерной формы уриказы и уриказа, полученная данным способом
PT2158923E (pt) * 1998-08-06 2013-06-04 Univ Duke Conjugados de peg-urato oxidase e sua utilização
NZ513077A (en) * 1999-01-14 2004-03-26 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
ES2538357T3 (es) * 2005-04-11 2015-06-19 Crealta Pharmaceuticals Llc Formas variantes de urato oxidasa y uso de las mismas
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
CA2604545A1 (en) * 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. A variant form of urate oxidase and use thereof
US20130305398A1 (en) * 2012-02-16 2013-11-14 Marie Coffin Genes and uses for plant enhacement
EP2698433A1 (en) * 2007-06-06 2014-02-19 Monsanto Technology LLC Genes and uses for plant enhancement
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CN103184209B (zh) * 2011-12-27 2015-09-16 拜奥生物科技（上海）有限公司 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用
CN107614007B (zh) 2015-05-15 2022-03-25 免疫医疗有限责任公司 改进的尿酸酶序列和治疗方法

Also Published As

Publication number Publication date
CL2017002774A1 (es) 2018-04-06
JP2021184733A (ja) 2021-12-09
US20180258406A1 (en) 2018-09-13
RU2017143580A3 (enExample) 2019-12-16
MY190411A (en) 2022-04-21
JP2018515101A (ja) 2018-06-14
ZA201708507B (en) 2018-11-28
HK1252542A1 (zh) 2019-05-31
US10883087B2 (en) 2021-01-05
AU2022200104A1 (en) 2022-02-03
US20190048327A1 (en) 2019-02-14
IL255403A0 (en) 2017-12-31
RU2752497C2 (ru) 2021-07-28
AU2016265677A1 (en) 2018-01-04
AU2016265677B2 (en) 2021-12-09
EP3294322A1 (en) 2018-03-21
CN107614007B (zh) 2022-03-25
US20210254024A1 (en) 2021-08-19
BR112017024212A2 (pt) 2018-07-17
CA2984926A1 (en) 2016-11-24
CO2017012454A2 (es) 2018-04-30
CN107614007A (zh) 2018-01-19
SG10201910522TA (en) 2020-01-30
WO2016187026A1 (en) 2016-11-24
US11098289B2 (en) 2021-08-24
KR20180002828A (ko) 2018-01-08
MX2017014547A (es) 2018-03-15
EP3294322A4 (en) 2018-12-12
RU2017143580A (ru) 2019-06-17

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
ZA201708507B (en) Improved uricase sequences and methods of treatment
IL274865A (en) Treatment methods with asparaginase
SI3285777T1 (sl) Glikanski terapevtiki in postopki zdravljenja
IL282482A (en) Variants of protoxin-II and methods of use
ZA201706059B (en) Method of treatment with tradipitant
IL265359A (en) Modified Oligonucleotides and Methods of Use
IL282508A (en) Variants of protoxin-II and methods of use
EP3684342C0 (en) TREATMENT PROCEDURES
PL3183003T3 (pl) SPOSOBY ZAPOBIEGANIA l/LUB LECZENIA ZAKAŻENIA
GB201706406D0 (en) Method of treatment
GB201815588D0 (en) Method of treatment
IL254825A0 (en) Methods of treatment with Tesalisib
ZA201705847B (en) Treatment of pain
EP3134108A4 (en) Agents and methods of treatment
GB201416832D0 (en) Methods of treatment
GB201511799D0 (en) Composition and methods of treatment
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201621737D0 (en) Compositions and methods of treatment
GB201602802D0 (en) Method of treatment
GB201605127D0 (en) Composition and methods of treatment
GB201417248D0 (en) Compostion and methods of treatment
ZA201802201B (en) Novel formulation and treatment methods
GB201512139D0 (en) Methods of treatment
GB201720439D0 (en) Method of treatment